Navigation Links
Optimer Pharmaceuticals Reports Second Quarter 2012 Financial Results
Date:7/31/2012

SAN DIEGO, July 31, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the Company's financial results for the quarter ended June 30, 2012.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

Second Quarter 2012 Financial Highlights:

  • DIFICID® second quarter gross sales of $18.0 million and net sales of $15.2 million, represent increases of 9% and 6% over the first quarter, respectively
  • DIFICID ex-wholesaler treatments shipped in the second quarter to hospitals, retail pharmacies and long-term care facilities increased by 11%
  • Surpassed the first-year net sales goal established with Cubist, triggering a $5 million milestone payment due to Cubist
  • Total revenues were $49.8 million, including $19.9 million for partnering with Astellas in Japan and a $12.6 million milestone from Astellas Pharma Europe for the launch of DIFICLIR™ in the EU
  • Cash, cash equivalents and short-term investments at June 30 totaled $130.6 million
  • Net loss for the second quarter was $296,000, or $0.01 per share
  •  

    "July marked the one-year anniversary of the launch of DIFICID, and we are very proud of our accomplishments. We've generated $51.1 million in net sales and shipped almost 21,000 treatments of DIFICID since launch through the end of June this year," stated Pedro Lichtinger, President and Chief Executive Officer of Optimer. "Both demand for, and access to, DIFICID continue to grow, as scientific and health economic understanding is being expanded through more than 90 publications to date. We are confident in DIFICID's potential to meet our expectations in 2012 and also maintain expectations for reaching break-even within 3 years of launch."

    Financial Overview
    Total revenues for the thr
    '/>"/>

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
    2. Global Biopharmaceuticals Market 2011-2015
    3. Patient Advocate Foundation and Jazz Pharmaceuticals Announce Partnership for Narcolepsy CareLine
    4. Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain
    5. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
    6. Keryx Biopharmaceuticals to Present at The 7th Annual JMP Securities Healthcare Conference
    7. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
    8. Access Pharmaceuticals to Report New MuGard Clinical Trial Data This Week at the MASCC/ISOO Symposium in New York City
    9. Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day
    10. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
    11. Questcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
    (Date:12/22/2014)... 22, 2014 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... focused on the development of autologous cell therapies, announced ... University of Calgary in conjunction with co-authors from Kyoto ... validates the company,s ongoing clinical research using dermal sheath ... baldness. The paper entitled " Hair Follicle ...
    (Date:12/22/2014)... ITRA Global, one of the largest organizations ... estate, has further expanded its global reach with the ... Western Australia, reports Mylinda Vick, CCIM, Chairman of the ... / ACORPP (Australian Corporate Property and Projects) , is ... services to a wide range of clients in the ...
    (Date:12/19/2014)... , Dec. 19, 2014 Naurex Inc., ... novel drugs for diseases of the central nervous system, ... and chief executive officer, will present at the 33 ... presentation will take place at 3:00 p.m. PST on ... in San Francisco, Calif. ...
    Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
    ... The bread and butter of Wisconsins economic growth will ... capital to transfer our best technology to the marketplace, ... and ensuring theres a 21st century infrastructure in place ... side to the equation, too, that may prove as ...
    ... a provider of supply chain execution (SCE) ... supplier compliance and inbound productivity by providing ASN ... Link and CatalystConnect SL are part of ... OAG (Open Application Group) XML interface standards. The ...
    ... WI Governor Jim Doyle today announced his "Grow ... of the recommendations is to increase broadband and ... , ,Mike Tye, AT&T regional vice present of ... encouraged by the "Grow Wisconsin" initiative unveiled today ...
    Cached Biology Technology:Athletics, pop culture and the arts 2Athletics, pop culture and the arts 3Software Enables Suppler Customer Data Integration 2
    (Date:12/22/2014)... 2014 Research and Markets ... of the "The Global Watermarking and ... http://photos.prnewswire.com/prnh/20130307/600769 ... of the global digital media watermarking and ... monitor piracy by securely and invisibly embedding ...
    (Date:12/19/2014)...  23andMe, Inc., the leading personal genetics company, today ... differences in genetic ancestry of individuals from across ... immigrants first arrived more than four hundred years ago, ... as a meeting place for peoples from different continents. ... mixing of peoples with African, European, and American origins ...
    (Date:12/17/2014)...  HITLAB SM announced today its completion ... confirm its adherence to current U.S. Food and ... to conduct regulated smart device and smart phone ... safety and research quality. "HITLAB is ... delivery with innovative technology," said Laura Pugliese ...
    Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
    ... Scientific progress in Huntington,s disease (HD) relies upon the ... the disease,s genetics and/or pathophysiology. Large animal models, such ... rodent models, including a larger brain that is amenable ... more human-like neuro-architecture. Three articles in the latest issue ...
    ... to osteoporosis are a major cause of disability or premature ... who have already suffered one fragility fracture; they are at ... others who have not fractured. Nevertheless health care ... these patients, leaving them exposed to debilitating and life-threatening secondary ...
    ... and wild plants has concluded they are under threat ... decline or loss could have profound environmental, human health ... services to about 75% of crop species and enable ... Pollination services provided by insects each year worldwide are ...
    Cached Biology News:Large animal models of Huntington's disease offer new and promising research options 2Large animal models of Huntington's disease offer new and promising research options 3Large animal models of Huntington's disease offer new and promising research options 4New review sets international standards for best practice in fracture liaison services 2Cocktail of multiple pressures combine to threaten the world's pollinating insects 2
    ... Gelzyme is an agarose-digesting enzyme ... cleaves simple carbohydrate bonds in agarose ... longer gel. The remaining carbohydrate molecules ... manipulation. DNA isolated with Gelzyme enzyme ...
    RAT ANTI MOUSE METALLOPHILIC MACROPHAGES...
    S. O'Hare & C.K. Atterwill • In vitro toxicity techniques for regular lab use. Ex vivo techniques are also covered with the aim of reducing and refining the use of animals in the future....
    Form: Ready to use Applications: ELISA...
    Biology Products: